Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
Lyfnua 45 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Pink, 10 mm, round and convex tablet debossed with “777” on one side and plain on the other side. |
Each film-coated tablet contains gefapixant citrate equivalent to 45 mg of gefapixant.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Gefapixant |
Gefapixant is a selective antagonist of the P2X3 receptor. P2X3 receptors are ATP-gated ion channels found on sensory C fibres of the vagus nerve in the airways. C fibres are activated in response to inflammation or chemical irritants. Blockade of ATP signalling through P2X3 receptors reduces excessive sensory-nerve activation and excessive cough induced by extracellular ATP. |
| List of Excipients |
|---|
|
Tablet core: Silica, collodial anhydrous (E551) Film-coating: Hypromellose (E464) |
Opaque white PVC/PE/PVdC blisters with push through aluminium lidding foil. Packs of 28, 56 and 98 film-coated tablets in non-perforated blisters (14 tablets per card) and multipacks containing 196 (2 packs of 98) film-coated tablets in non-perforated blisters.
Not all pack sizes may be marketed.
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
EU/1/21/1613/001
EU/1/21/1613/002
EU/1/21/1613/003
EU/1/21/1613/004
| Drug | Countries | |
|---|---|---|
| LYFNUA | Estonia, Croatia, Ireland, Italy, Japan, Lithuania |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
